Showing 3651-3660 of 5646 results for "".
- Science Corporation: PRIMA Clinical Trials Show Restoration of "Form Vision"https://modernod.com/news/science-corporation-announces-breakthrough-in-retinal-implant-technology-prima-clinical-trials-show-restoration-of-form-vision/2482509/Science Corporation, a developer in brain-computer interface (BCI) technology, has announced preliminary results from clinical trials of its PRIMA retina implant. This technology has demonstrated the ability to restore what the company is calling 'form vision' in patients suffer
- Ocuphire Acquires Gene Therapy Company Opus Geneticshttps://modernod.com/news/ocuphire-acquires-gene-therapy-company-opus-genetics/2482508/Ocuphire Pharma announced an all-stock acquisition of Opus Genetics, a clinical-stage gene therapy company specializing in inherited retinal diseases (IRDs). As part of the deal, the combined company will be renamed Opus Genetics, effective October 23, 2024, and will begin trading under the
- Cathleen McCabe, MD, Appointed Strategic Medical Advisor at Bausch + Lombhttps://modernod.com/news/cathleen-mccabe-md-appointed-strategic-medical-advisor-at-bausch-lomb/2482507/Bausch + Lomb has appointed Cathleen McCabe, MD, as Strategic Medical Advisor. According to B+L, in this new consultancy role, Dr. McCabe will contribute her expertise to Bausch + Lomb’s product portfolio expansion and collaborate with the research and development team to drive in
- Oculis Accelerates Enrollment for Phase 3 DIAMOND Trials of OCS-01 Eye Drops in DMEhttps://modernod.com/news/oculis-accelerates-enrollment-for-phase-3-diamond-trials-of-ocs-01-eye-drops-in-diabetic-macular-edema/2482504/Oculis announced significant progress in patient enrollment for both phase 3 DIAMOND trials of OCS-01 eye drops in diabetic macular edema (DME). The DIAMOND program, designed to assess the efficacy and safety of OCS-01, an investigational eye drop, has enrolled about 70% of patients in the phase
- Regenxbio Reports Positive Phase 2 Data on ABBV-RGX-314 for Bilateral Wet AMDhttps://modernod.com/news/regenxbio-reports-positive-phase-2-data-on-abbv-rgx-314-for-bilateral-wet-amd/2482503/Regenxbio announced results from the phase 2 fellow eye sub-study evaluating the subretinal delivery of ABBV-RGX-314, a gene therapy candidate, in patients with bilateral wet age-related macular degeneration (AMD). The data was presented at the American Academy of Ophthalmology (AAO) me
- Google’s Diabetic Retinopathy AI Model Licensed for Use in India and Thailandhttps://modernod.com/news/googles-diabetic-retinopathy-ai-model-licensed-for-use-in-india-and-thailand/2482497/Google announced the licensing of its diabetic retinopathy artificial intelligence (AI) model to healthcare providers and health-tech partners. According to Google, during the next 10 years, Forus Health, AuroLab, and Perceptra will aim to deliver a combined 6 million AI-supported scree
- Glaukos Announces Positive Phase 3 Results for Epioxa Corneal Cross-Linking Therapyhttps://modernod.com/news/glaukos-announces-positive-phase-3-results-for-epioxa-corneal-cross-linking-therapy/2482495/Glaukos announced that its second phase 3 confirmatory pivotal trial for Epioxa (Epi-on), a next-generation corneal cross-linking therapy for the treatment of keratoconus, has met its primary efficacy endpoint. The trial demonstrated a statistically significant and clinically
- Ikerian and RetinAI Secure $8M Financing to Drive AI Healthcare Innovationhttps://modernod.com/news/ikerian-and-retinai-secure-8m-financing-to-drive-ai-healthcare-innovation/2482494/Switzerland-based Ikerian AG and its subsidiary RetinAI US, announced the successful first close of their Series B financing round, securing USD $8 million (CHF 6.73 million). With the newly secured funding, Ikerian said it is set to fast-track the development of its flagship produ
- Oculis to Provide Update on DIAMOND Phase 3 Program for OCS-01 Eye Drops at Innovate Retina and Eyecelerator 2024https://modernod.com/news/oculis-to-provide-update-on-diamond-phase-3-program-for-ocs-01-eye-drops-at-innovate-retina-and-eyecelerator-2024/2482488/Oculis announced an update on its DIAMOND phase 3 program for OCS-01, a high-concentration dexamethasone eye drop formulated with OPTIREACH technology for the treatment for diabetic macular edema (DME). David Eichenbaum, MD, an expert in retina diseases, will present new insig
- Centricity Vision Unveils Enhancements to ZEPTOLink IOL Positioning System at AAO 2024https://modernod.com/news/centricity-vision-unveils-enhancements-to-zeptolink-iol-positioning-system-at-aao-2024/2482487/Centricity Vision announced platform enhancements for its ZEPTOLink IOL Positioning System designed to reduce treatment time by up to 60%. The enhancements will be highlighted at the American Academy of Ophthalmology (AAO) annual meeting, taking place from October 18-21, 2024, in Chicago.